Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients
Article first published online: 15 JAN 2009
© 2009 The Authors. Journal compilation © 2009 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 23, Issue 4, pages 415–419, April 2009
How to Cite
Brunasso, A., Salvini, C. and Massone, C. (2009), Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients. Journal of the European Academy of Dermatology and Venereology, 23: 415–419. doi: 10.1111/j.1468-3083.2008.03062.x
- Issue published online: 17 MAR 2009
- Article first published online: 15 JAN 2009
- Received: 7 April 2008; Accepted 22 August 2008
- palmo-plantar psoriasis;
Background Palmo-plantar psoriasis (PPP) is a disabling condition that significantly impairs quality of life. PPP tends to be resistant to conventional therapies and may last for several years. Topical treatments are usually ineffective. Systemic therapy with oral retinoids and psoralen plus ultraviolet A is frequently required, although it rarely leads to remission.
Study design We conducted an open-label, pilot study to evaluate treatment of PPP with efalizumab, an anti-CD11a monoclonal antibody approved for the treatment of chronic, refractory moderate to severe plaque psoriasis in adults.
Methods Five patients with severe PPP received efalizumab treatment for 24 weeks.
Results All five patients responded favourably by week 12 and showed further improvement at week 24 of uninterrupted therapy. Mean physician-assessed severity scores and patient-reported outcome scores improved almost 75% after 12 weeks and 90% after 24 weeks. At week 32, three patients maintained the response seen at week 24, while two patients suspended efalizumab.
Conclusions Efalizumab therapy was well tolerated and effective in five patients with severe PPP, allowing a significant improvement in quality of life.
Conflicts of interest